Bacterial sexually transmitted infections like syphilis, chlamydia, and gonorrhea are rising sharply across the globe, and the Philippines is no exception. While condoms remain a frontline prevention method, researchers have been investigating whether a common antibiotic could offer an additional layer of protection after a potential exposure. That antibiotic is doxycycline, and the strategy is called Doxy-PEP. If you have been following developments in sexual health, you may have come across this term in recent news or discussions with your healthcare provider. This guide explains what Doxy-PEP is, how it works, who it is for, and what it means for STI prevention in the Philippines.
~87%
Reduction in syphilis
~88%
Reduction in chlamydia
200mg
Single dose within 72 hours
What does Doxy-PEP stand for?
Doxy-PEP stands for Doxycycline Post-Exposure Prophylaxis. Breaking that down:
- Doxycycline is a tetracycline-class antibiotic that has been in clinical use for decades. It is commonly prescribed for acne, respiratory infections, malaria prevention, and certain STIs.
- Post-Exposure means the medication is taken after a potential exposure to an infection, not before.
- Prophylaxis means a treatment used to prevent a disease from developing.
In practical terms, Doxy-PEP involves taking a single dose of doxycycline after condomless sexual contact in order to reduce the risk of acquiring certain bacterial STIs. It does not prevent HIV or viral STIs such as herpes or HPV. Think of it as a targeted antibiotic safety net used after the fact.
How does Doxy-PEP work?
Doxycycline works by inhibiting bacterial protein synthesis. When bacteria like Treponema pallidum (which causes syphilis) or Chlamydia trachomatis enter the body during sexual contact, the antibiotic interferes with their ability to grow and reproduce. If enough of the drug is present in the body's tissues soon after exposure, it can eliminate the bacteria before they establish an infection.
The concept is similar to how PEP (Post-Exposure Prophylaxis) works for HIV prevention, where antiretroviral medication is taken after a potential HIV exposure to stop the virus from taking hold. Doxy-PEP applies the same principle to bacterial STIs using an antibiotic instead of antiretrovirals.
How to take Doxy-PEP
The protocol studied in clinical trials is straightforward:
How to take Doxy-PEP
Have condomless sexual contact
Take 200mg doxycycline (two 100mg capsules)
Take it within 24-72 hours after exposure
Do not exceed one dose per 24-hour period
Continue regular STI screening as recommended
The dose is 200mg of doxycycline, taken as a single dose ideally within 24 hours of condomless sex, but the window extends up to 72 hours. If you have multiple sexual encounters within a 24-hour period, only one dose is needed for that window. The maximum recommended dose is 200mg in any 24-hour period.
Doxy-PEP is not meant to replace daily medications. It is taken on an as-needed basis after each potential exposure event.
Which STIs does Doxy-PEP prevent?
Clinical trials have shown that Doxy-PEP is effective against two of the three most common bacterial STIs, with limited effectiveness against the third.
Syphilis
Doxycycline has demonstrated the strongest evidence for syphilis prevention. In the landmark DoxyPEP trial, participants who took doxycycline after condomless sex saw an approximately 87% reduction in syphilis infections compared to those who did not take the antibiotic. This is particularly significant given the global resurgence of syphilis in the Philippines, where cases among young adults have risen sharply in recent years.
Chlamydia
The evidence for chlamydia prevention is similarly strong. The same trial showed an approximately 88% reduction in chlamydia infections. Since chlamydia is often asymptomatic and can cause long-term complications if untreated, including pelvic inflammatory disease and infertility, preventing it at the point of exposure is a valuable clinical tool.
Gonorrhea
This is where the picture becomes more complicated. Doxy-PEP showed limited and inconsistent effectiveness against gonorrhea. In the DoxyPEP trial, the reduction in gonorrhea infections was not statistically significant. The reason is that Neisseria gonorrhoeae, the bacterium that causes gonorrhea, already has high rates of tetracycline resistance in many regions. In settings where gonorrhea strains are resistant to doxycycline, the antibiotic simply cannot prevent the infection.
This is an important limitation. If gonorrhea is your primary concern, Doxy-PEP alone is unlikely to provide reliable protection. Condom use and regular testing remain essential.
The clinical evidence
Several major clinical trials have built the evidence base for Doxy-PEP. Understanding these studies helps contextualize the recommendations.
The DoxyPEP trial (2022)
The DoxyPEP trial, published in the New England Journal of Medicine in 2022, is the most influential study to date. Conducted in the United States, it enrolled men who have sex with men (MSM) and transgender women who were either on PrEP or living with HIV. Participants were randomized to either take 200mg of doxycycline within 72 hours of condomless sex or to receive standard care without doxycycline.
The results were striking. The doxycycline group experienced a two-thirds overall reduction in bacterial STIs. Syphilis infections dropped by approximately 87%, chlamydia by approximately 88%, and there was a modest but not statistically significant reduction in gonorrhea. The study established the clinical credibility of this approach and became the basis for subsequent guidelines.
The IPERGAY OLE study
Before DoxyPEP, the French IPERGAY Open-Label Extension study provided early evidence. This smaller study in MSM taking PrEP in France found that on-demand doxycycline use reduced the incidence of syphilis and chlamydia by approximately 70%. While the study had limitations, including a smaller sample size and an open-label design, it was the first randomized trial to suggest that post-exposure doxycycline could work as STI prophylaxis.
The DOXYVAC trial
Also conducted in France, the DOXYVAC trial studied Doxy-PEP alongside a meningococcal B vaccine (to test whether the vaccine might also reduce gonorrhea). The doxycycline arm of this trial confirmed the findings of DoxyPEP, showing significant reductions in syphilis and chlamydia among MSM participants. The trial was stopped early due to the clear efficacy signal.
Importantly, the DOXYVAC trial also included a sub-analysis that found no significant benefit of Doxy-PEP among cisgender women in a parallel Kenyan study. This finding has shaped current recommendations about who should and should not use Doxy-PEP.
Who is Doxy-PEP recommended for?
Based on the clinical trial evidence and the CDC guidelines issued in 2023, Doxy-PEP is recommended for:
- Men who have sex with men (MSM) who have had a bacterial STI in the past 12 months
- Transgender women who have had a bacterial STI in the past 12 months
- People in the above groups who are currently on PrEP or living with HIV
The CDC framed Doxy-PEP as a shared clinical decision between the patient and healthcare provider, meaning it is not a blanket recommendation for everyone but a tool to be considered based on individual risk. The key eligibility factor is a recent history of bacterial STIs, which signals ongoing exposure risk.
Who is Doxy-PEP not recommended for?
The evidence does not currently support Doxy-PEP for all populations:
- Cisgender women: The Kenyan dPEP trial, a randomized controlled trial conducted among cisgender women, did not show a statistically significant reduction in STIs with Doxy-PEP use. The biological reasons are not entirely clear but may relate to differences in doxycycline tissue concentration in vaginal versus rectal tissue, or differences in the types of sexual exposure. Until further evidence emerges, Doxy-PEP is not recommended for cisgender women.
- People with tetracycline allergies: Doxycycline belongs to the tetracycline class, and anyone with a known allergy to this class of antibiotics should not take it.
- Pregnant or breastfeeding individuals: Doxycycline is contraindicated in pregnancy due to the risk of tooth discoloration and bone growth effects in the developing fetus.
- Children under 8 years old: Tetracyclines are not recommended in young children for similar reasons.
If you fall outside the recommended groups, discuss other STI prevention strategies with your healthcare provider. Condom use, regular screening, and prompt treatment of infections remain foundational.
Side effects of Doxy-PEP
Doxycycline is a well-established medication with a known side-effect profile. Most side effects are mild and temporary:
- Gastrointestinal issues are the most common complaint. These include nausea, stomach upset, diarrhea, and occasionally vomiting. Taking the medication with food and a full glass of water can reduce GI symptoms.
- Photosensitivity is a well-documented effect of doxycycline. Your skin becomes more sensitive to sunlight, increasing the risk of sunburn. This is particularly relevant in the Philippines, where UV exposure is high year-round. Use sunscreen and protective clothing if you are taking doxycycline.
- Yeast infections (candidiasis) can occur because antibiotics disrupt the body's normal microbial balance. This is more commonly reported in people with vaginal flora.
- Esophageal irritation can occur if the capsule is taken without enough water or if you lie down immediately after taking it. Always take doxycycline with a full glass of water and remain upright for at least 30 minutes afterward.
Because Doxy-PEP involves taking the antibiotic on an as-needed basis rather than daily, the overall side-effect burden is generally lower than with chronic doxycycline use.
Antibiotic resistance: the main debate
The widespread use of Doxy-PEP could accelerate antibiotic resistance. This is the most significant concern among public health experts and the reason why Doxy-PEP should only be used under medical guidance, not as self-medication.
Antibiotic resistance is the central tension in the Doxy-PEP conversation. Every time an antibiotic is used, there is a chance that bacteria exposed to it will develop resistance, making the drug less effective over time. The concern with Doxy-PEP is that widespread, repeated use of doxycycline across a population could:
- Accelerate tetracycline resistance in Neisseria gonorrhoeae, which already shows high resistance rates in many regions including Southeast Asia.
- Drive resistance in other bacteria, including normal flora of the gut, skin, and respiratory tract. This could make doxycycline less effective for treating other common infections such as respiratory tract infections and acne.
- Affect other classes of antibiotics through cross-resistance mechanisms, where resistance to one antibiotic can confer resistance to others.
Researchers are actively monitoring resistance patterns in populations using Doxy-PEP. Early data from the DoxyPEP trial follow-up did show some increase in tetracycline-resistant bacteria among participants taking doxycycline, though the clinical significance of this finding is still being evaluated.
This is why Doxy-PEP is recommended within a clinical framework with ongoing STI surveillance, not as an over-the-counter solution. Self-medicating with doxycycline without medical supervision contributes to the resistance problem and is strongly discouraged.
Doxy-PEP vs. condoms vs. regular STI screening
No single prevention method works perfectly on its own. The strongest approach combines multiple strategies. Here is how the main options compare:
Comparing STI prevention methods
| Doxy-PEP | Condoms | |
|---|---|---|
| Prevents bacterial STIs | Syphilis and chlamydia (high); gonorrhea (limited) | All STIs when used correctly and consistently |
| Prevents viral STIs (HIV, HSV, HPV) | No | Yes (reduces risk significantly) |
| When to use | Within 72 hours after exposure | During sexual contact |
| Requires prescription | Yes | No |
| Side effects | GI upset, photosensitivity | None (possible latex allergy) |
| Resistance concern | Yes (antibiotic resistance) | No |
Regular STI screening is not a prevention method in itself, but it is a critical component of sexual health. Screening identifies infections early, enables prompt treatment, and prevents onward transmission. Whether or not you use Doxy-PEP or condoms, routine testing every 3 to 6 months is recommended for sexually active individuals at higher risk.
The ideal approach for many people is a combination of condoms, regular screening, and, when appropriate, Doxy-PEP. These strategies are complementary, not mutually exclusive.
Availability in the Philippines
As of early 2026, Doxy-PEP is not yet widely available or formally integrated into public health guidelines in the Philippines. The Department of Health (DOH) has not yet issued specific guidelines on Doxy-PEP use, and it is not part of the standard STI prevention package offered at social hygiene clinics or DOH treatment hubs.
However, doxycycline itself is widely available in the Philippines as a prescription medication. It is inexpensive, with generic versions costing as little as PHP 5 to PHP 15 per 100mg capsule at most pharmacies. The medication is also used routinely for treating active STIs, particularly syphilis and chlamydia.
If you are interested in Doxy-PEP, the most practical path currently is to discuss it with your doctor. An infectious disease specialist, a sexual health clinician, or a healthcare provider at an HIV treatment hub will be most familiar with the evidence. You can find treatment hubs and clinics through our facility directory. Some community-based organizations serving MSM and transgender populations may also be aware of the approach and able to facilitate a conversation with a clinician.
It is important to avoid purchasing doxycycline from unauthorized sellers or using it without medical supervision. Using antibiotics without proper guidance contributes to resistance and may give a false sense of protection.
How to talk to your doctor about Doxy-PEP
Bringing up Doxy-PEP with your healthcare provider can feel uncomfortable, especially in settings where discussing sexual health openly may carry stigma. Here are some practical suggestions:
-
Choose the right provider. If your primary care physician is not comfortable discussing sexual health in detail, consider seeking out an infectious disease specialist, a dermatologist who treats STIs, or a clinician at a social hygiene clinic or HIV treatment hub.
-
Be direct. You can say something like: "I have been reading about doxycycline post-exposure prophylaxis for STI prevention. Based on my risk factors, I would like to discuss whether it might be appropriate for me."
-
Share your risk history honestly. Your doctor needs to understand your sexual practices, number of partners, condom use patterns, and history of STIs to make a well-informed recommendation. This information is confidential and protected under R.A. 11166 (the Philippine HIV and AIDS Policy Act).
-
Ask about monitoring. If your doctor agrees that Doxy-PEP is appropriate, ask about a plan for regular STI screening, typically every 3 months. This ensures that any breakthrough infections are caught and treated early.
-
Discuss antibiotic resistance. A thoughtful provider will weigh the individual benefit of Doxy-PEP against the population-level risk of antibiotic resistance. This is a legitimate conversation to have, and it reflects responsible use of the intervention.
Frequently asked questions
Is Doxy-PEP the same as taking antibiotics before sex? No. Doxy-PEP is taken after a potential exposure, not before. Taking antibiotics before sex has not been studied in the same way, and routine pre-exposure antibiotic use for STI prevention is not recommended.
Can I take Doxy-PEP every day? Doxy-PEP is not intended for daily use. It is designed to be taken on-demand, after condomless sexual contact. The maximum recommended dose is 200mg in a 24-hour period. If you are having frequent exposures, discuss your overall prevention strategy with your doctor.
Does Doxy-PEP protect against HIV? No. Doxycycline is an antibiotic and has no effect on HIV, which is a virus. If you need HIV prevention, ask your doctor about PrEP (Pre-Exposure Prophylaxis). You can learn more in our PrEP guide for Filipinos.
Can I buy doxycycline over the counter in the Philippines? Doxycycline is a prescription medication in the Philippines. While enforcement varies, you should always obtain it with a prescription from a licensed healthcare provider. Self-medication with antibiotics is unsafe and contributes to antibiotic resistance.
What if I am allergic to doxycycline? If you have a known allergy to tetracycline-class antibiotics, you should not take Doxy-PEP. Discuss alternative STI prevention strategies with your doctor, including consistent condom use and more frequent STI screening.
Does Doxy-PEP work against oral or anal gonorrhea? The evidence for Doxy-PEP against gonorrhea at any anatomical site is limited. Gonorrhea strains with tetracycline resistance are common, particularly in Southeast Asia. Condom use and regular screening remain the best strategies for gonorrhea prevention.
How soon after sex should I take Doxy-PEP? The sooner, the better. The clinical trials established a window of up to 72 hours, but taking the dose within 24 hours of exposure is ideal for maximum effectiveness.
Will my doctor judge me for asking about Doxy-PEP? A competent sexual health provider will not judge you. Discussing prevention options is a normal and responsible part of healthcare. If you feel uncomfortable with your current provider, consider seeking out a clinician who specializes in sexual health or HIV care.
Sources and references
- CDC. "About STIs." https://www.cdc.gov/sti/about/index.html
- WHO. "Sexually Transmitted Infections (STIs) Fact Sheet." https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
- Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. New England Journal of Medicine. 2023;388(14):1296-1306.
- Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. The Lancet Infectious Diseases. 2018;18(3):308-317.
- Molina JM, Bercot B, Assoumou L, et al. ANRS 174 DOXYVAC: An Open-Label Randomized Trial to Prevent STIs in MSM on PrEP. Conference on Retroviruses and Opportunistic Infections (CROI). 2023.
- Centers for Disease Control and Prevention (CDC). Doxy-PEP (Doxycycline Post-Exposure Prophylaxis) for STI Prevention: Clinical Guidance. 2023.
- Stewart J, Oware K, Donnell D, et al. Doxycycline Post-exposure Prophylaxis for Prevention of STIs Among Cisgender Women. Conference on Retroviruses and Opportunistic Infections (CROI). 2024.
- World Health Organization (WHO). Global progress report on HIV, viral hepatitis and sexually transmitted infections. 2021.
- Department of Health (DOH), Philippines. HIV/AIDS and ART Registry of the Philippines (HARP). 2024 Report. https://doh.gov.ph/
